Currently out of the existing stock ratings of Marc Goodman, 186 are a BUY (77.18%), 49 are a HOLD (20.33%), 6 are a SELL (2.49%).

Marc Goodman

Work Performance Price Targets & Ratings Chart

Analyst Marc Goodman, currently employed at LEERINK, carries an average stock price target met ratio of 59.13% that have a potential upside of 34.27% achieved within 335 days.

Marc Goodman’s has documented 438 price targets and ratings displayed on 44 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on AMLX, Amylyx Pharmaceuticals at 06-May-2025.

Wall Street Analyst Marc Goodman

Analyst best performing recommendations are on KRTX (KARUNA THERAPEUTICS).
The best stock recommendation documented was for KRTX (KARUNA THERAPEUTICS) at 8/9/2022. The price target of $270 was fulfilled within 3 days with a profit of $41.55 (18.19%) receiving and performance score of 60.63.

Average potential price target upside

of $106.85 (28.34%) on REGN (REGENERON PHARMACEUTICALS).
of $79.49 (30.44%) on BIIB (BIOGEN).
of $68.19 (58.43%) on GWPH (GW PHARMACEUTICALS PLC).

ABBV AbbVie ACAD ACADIA Pharmaceuticals AGN Allergan plc ALDX Aldeyra The AXSM Axsome Therapeutics BHVN Biohaven Pharmaceutical Holding Co Ltd BMY Bristol-Myers Squibb Company GILD Gilead Sciences GMTX Gemini Therapeutics JAZZ Jazz Pharmaceuticals PLC LLY Eli Lilly and Company MNK Mallinckrodt plc MRK Merck mpany MYL Viatris NBIX Neurocrine Biosciences PRGO Perrigo Company PLC REGN Regeneron Pharmaceuticals SAGE Sage Therapeutic VRTX Vertex Pharmaceuticals ZGNX Zogenix ALKS Alkermes Plc HZNP Horizon Pharma PLC APTX Aptinyx AVDL Avadel Pharmaceuticals PLC GRAY Graybug Vision KRTX Karuna Therapeutics AMLX Amylyx Pharmaceuticals ELYM Eliem Therapeutics MRNS Marinus Pharmaceuticals VTRS Viatris XENE Xenon Pharmaceuticals ITCI Intracellular Th STSA Satsuma Pharmaceuticals BIIB Biogen ACIU AC Immune Ltd ADMS Adamas Pharmaceuticals ENDP Endo International PLC EOLS Evolus GWPH GW Pharmaceuticals plc NEOS Neos Therapeutics PFE Pfizer RLMD Relmada Therapeutics ALDR Alder BioPharmaceuticals OPT Opthea Ltd

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Christopher Raymond (RAYMOND JAMES)